LAF3 Rec'd PCT/PTO 3 0 MAR 2006





File No.: 6013-129US MG/lyl

Québec, Canada

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Philippe Tessier et al.

Serial No.:

10/551,234

Filing Date:

September 27, 2005

Art Unit:

Unknown

Title:

S100 PROTEIN AS NEUTROPHIL ACTIVATOR FOR

ALLEVIATING NEUTROPENIA IN CANCER TREATMENT

SECOND INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

NO FEE

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on a PTO/SB/08A/B form is a listing of the documents known to applicant in order to comply with applicant's duty of disclosure pursuant to 37 C.F.R. § 1.56.

The submission of any document which is not a statutory bar is not intended as an admission that such document constitutes prior art against the claims of the present application. Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a <u>prima facie</u> prior art reference against the claims of the present application.

Statement of Relevancy

The listed document is being submitted either in compliance with

37 C.F.R. §1.97(b), within three (3) months of the filing date of a national

application or of the date of entry of the national stage in an international

application, or before the mailing of a first Office Action on the merits, or

before the mailing of a first Office Action after the filing of a request for

continued examination under §1.114; or pursuant to 37 C.F.R. §1.97(e)(1),

within three (3) months from the date of an office action or of a search report

issued in a foreign counterpart application citing each of the documents

contained in the present statement; or pursuant to 37 C.F.R. §1.97(e)(2), within

three (3) months from the first knowledge of each submitted document by any

individual designated in C.F.R. §1.56(c), when each such document was not

cited in a communication from a foreign patent office in a counterpart foreign

application.

In the case of submission under 37 C.F.R. §1.97(e)(1) and (2), the

undersigned Attorney/Agent of Record hereby certifies that the enclosed list of

references is hereby submitted within three months (1) from the issuance of the

foreign action or search report, or (2) from said first knowledge, respectively.

The Examiner is kindly requested to consider these references

during the examination of the above-identified application, making the

references of record, and to return an initialed copy of the PTO/SB/08A/B

Form to the below-signed agent.

Respectfully,

March 29, 2006

Date

Agent of the Applicant

Marie-Hélène Rochon, Reg. No. 57,566

Lelene Torkon

OGILVY RENAULT, LLP

Customer Number: 020988

1TO/SB/08A/B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Paperwork Refuction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.				
Sus Annual for form 1449A and B/PTO		Complete if Known		
		Application Number	10/551,234	
ORMATION	I DISCLOSURE	Filing Date	September 27, 2005	
TEMENT E	Y APPLICANT	First Named Inventor	Philippe Tessier	
		Art Unit	1614	
(use as many sheets as necessary)		Examiner Name		
1	5	Attorney Docket Number	6013-129US MG/lyl	
	ORMATION	OF form 1449A and B/PTO ORMATION DISCLOSURE ATEMENT BY APPLICANT	Application Number Filing Date First Named Inventor Art Unit (use as many sheets as necessary) Contact Application Number Filing Date First Named Inventor Art Unit Examiner Name	

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examin er Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²		
		AGUIAR-PASSETI et al. "Epithelioid cells from foreign-body granuloma selectively express the calcium-binding protein MRP-14, a novel down-regulatory molecule of macrophage activation." 1997, J. Leukoc. Biol. 62:852-858.			
		BARTHE et al. "Identification of "cystic fibrosis protein" as a complex of two calcium-binding proteins present in human cells of myeloid origin." 1991, Biochim. Biophys. Acta. 1096:175-177.			
		BRANDTZAEG et al. "Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. II. Normal and aberrant occurance in various epithelia." 1987, American Journal of Clinical Pathology 87:700-707.			
		BRANDTZAEG et al. "The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces." 1995, Adv. Exp. Muc. Immunol 371A:201-205.			
		BRUGGEN et al. "The molecular nature of the cystic fibrosis antigen (letter)." 1988, Nature, 331:570.			
		BUISMAN et al. "Effect of granulocyte colony-stimulating factor on the course of infection with gram-positive bacteria in mice during granulocytopenia induced by sublethal irradiation or cyclophosphamide." 1996, J. Infect. Dis.,174:417-421.			
		CORNISH et al. "S100 protein CP-10 stimulates myeloid cell chemotaxis without activation." 1996, J. Cell. Physiol. 166:427-437.			
		DALE et al. "Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin." 1985, American Journal of Clinical Pathology 84:24-34.			
		DELL'ANGELICA et al. "Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binidng protein from pig granulocytes." 1994, J. Biol. Chem. 269:28929-28936.			
		DONATO, R. "Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type." 1999, BIOCH. Biophys. Acta 1450:191-231.			
		EDGEWORTH et al. "Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells." 1991, J. Biol. Chem. 266:7706-7713.			

	 	,
Examiner	Date	
Signature	Considered	

^{*}EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

1TO/SB/08A/B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

equired to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A and BOOK THAT		Complete if Known		
		A HEAVE	Application Number	10/551,234
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	September 27, 2005
			First Named Inventor	Philippe Tessier
• • • • • • • • • • • • • • • • • • • •		711.1	Art Unit	1614
(use as many sheets as necessary)		Examiner Name		
Sheet	2	5	Attorney Docket Number	6013-129US MG/lyl

FROSCH et al. "Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis." 2000, Arthritis. Rheum, 43:628-637.
GIORGI et al. "Antinociceptive effect of the calcium-binding protein MRP-14 and the role played by neutrophils on the control inflammatory pain." 1998, J. Leukoc. Biol. 64:214-220.
GOTTSCH et al. "Calgranulin C has filariacidal and filariastatic activity." 1999, Infect Immun. 67:6631-6636.
GUIGNARD et al. "Identification and characterization of a novel human neutrophil protein related to the S100 family." 1995, Biochem. J. 309:395-401.
HARRISON et al. "Oxidation regulates the inflammatory properties of the murine S100 protein S100A8." 1999, J. Biol. Chem. 274:8561-8569.
HASHEMI et al. "Myeloid-related protein (MRP)-8 from cervico-vaginal secretions activates HIV replication." 2001, AIDS, 15:441-449.
HATTORRI et al. "Comparative study of the effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on generation and mobilization of neutrophils in cyclophosphamide-treated neutropenic mice." 1996, In Vivo, 10:319-328.
HITOMI et al. "A novel calcium-binding protein in amniotic fluid, CAAF1: Its molecular cloning and tissue distribution." 1996, J. Cell. Sci. 109:805-815.
HOFMANN et al. "RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulinpolypeptides." 1999, Cell. 97:889-901.
HUNTER et al. "High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14." 1998, J. Biol. Chem. 273:12427-12435.
ILG et al. "Amino acid sequence determination of human S100A12 (P6, calgranulin C, CGRP, CAAF1) by tandem mass spectrometry." 1996, Biochem. Biophys. Res. Commun. 225:146-150.
IVANOV et al. "Enzyme-linked immunosorbent assay for human MRP-8/MRP-14 proteins and their quantitation in plasma of hematological patients." 1996, Immunol. Lett. 49:7-13.

1			
	Examiner	Date	
	Signature	Considered	

^{*}EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

1TO/SB/08A/B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1994 of person are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A and B/PTO		Complete if Known		
			Application Number	10/551,234
INFORMATION DISCLOSURE			Filing Date	September 27, 2005
STATEMENT BY APPLICANT		First Named Inventor	Philippe Tessier	
			Art Unit	1614
(use as many sheets as necessary)		Examiner Name		
Sheet	3	5	Attorney Docket Number	6013-129US MG/lyl

	JINQUAN et al. "Psoriasin: A novel chemotactic protein." 1996, J. Invest. Dermatol., 107:5-10.
	KOCHER et al. "Functional chemotactic-factor CP-10 and MRP-14 are abundant in murine abscesses."
	1996, Infect. Immun. 64:1342-1350.
i l	
	KOIKE et al. "Regulation of myeloid-specific calcium binding protein synthesis by cytosolic protein kinase." 1992, Journal of Biochemistry 112:624-630.
	1992, Journal of Biochemistry 112:624-630.
1	
1	KOJIMA et al. "Human gingival crevicular fluid contains MRP8 (S100A8) and MRP14 (S100A9), two
	calcium-binding proteins of the S100 family." 2000, J. Dent. Res., 79:740-747.
	V
	KOMADA et al. "Novel specific chemotactic receptor for S100L protein on guinea pig eosinophils." 1996,
	Biochem. Biophys. Res. Commun. 220:871-874.
	KUNZ et al. "Macrophage marker 27E10 on human keratinocytes helps to differentiate discoid lupus
<u> </u>	erythematosus and Jessner's lymphocytic infiltration of the skin." 1999, Eur. J. Dermatol. 9:107-110.
	LAGASSE et al. "Cloning and expression of two human genes encoding calcium-binding proteins that are
	regulated during myeloid differentiation." 1988, Mol. Cell. Biol. 8:2402-2410.
	regulated during myelolo differentiation. 1500, Mor. Oct., Blot. 6.2462 2416.
	LAU et al. "A chemotactic S100 peptide enhances scavenger receptor and Mac-1 expression and
	cholesteryl ester accumulation in murine peritoneal macrophages in vivo." 1995, J. Clin. Invest. 95:1957-
	1965.
	LI et al. "S100β induction of the proinflammatory cytokine interleukin-6 in neurons." 2000, J. Neurochem.
	74:143-150.
]	LUGEDING at all files are able to the stand distribution and to the standard file of the Co2t binding and the ADDO
1	LUGERING et al. "Immunohistochemical distribution and serum levels of the Ca ²⁺ -binding proteins MRP8, PMRP14 and their heterodimeric form MRP8/14 in Crohn's disease." 1995, Digestion, 56:406-414
	FINITE 14 and their neterodiment form with order 14 in Order 5 disease. 1993, Digestion, 30.400-414
]	
I i	LUGERING et al. "Importance of combined treatment with IL-10 and IL-4, but not IL-13, for inhibition of
	monocyte release of the Ca(2+)-binding protein MRP8/14." 1997, Immunology, 91:130-134.
	LUGERING et al. "Serum 27E10 antigen: a new potential marker for staging HIV disease." 1995, Clin. Exp.
	Immunol, 101:249-253.

Examiner	Date	
Signature	Considered	

^{*}EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

1TO/SB/08A/B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A and the substitute for for form 1449A and the substitute for for form 1449A and th		Co	Complete if Known	
		Application Number	10/551,234	
		Filing Date	September 27, 2005	
ST/	STATEMENT BY APPLICANT		First Named Inventor	Philippe Tessier
0.7			Art Unit	1614
(use as many sheets as necessary)		Examiner Name		
Sheet	4	5	Attorney Docket Number	6013-129US MG/lyl

MADSEN, P. et al. "Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin." 1991, J. Invest. Dermatol. 97;701-712.
MARTI et al. "Host-parasite interaction in human onchocerciasis: Identification and sequence analysis of a novel human calgranulin." 1996, Biochem. Biophys. Res. Commun, 221:454-458.
MAYER et al. "Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice." 1991, J. Infect Dis., 163:584-590.
METCALF et al. "Proliferative effects of purified granulocyte colony-stimulating factor (G-CSF) on normal mouse hemopoietic cells." 1983, J. Cell. Physiol. 116:198-206.
METCALF, D. "Cellular Hematopoiesis in the Twentieth Century." 1999, Seminars in Hematology, 36:5-12.
MIRANDA et al. "Total chemical sythesis and chemotactic activity of human S100A12 (EN-RAGE)." 2001, FEBS Lett 488:85-90.
MURAO et al. "A protein complex expressed during terminal differentiation of monomyelocytic cells is an inhibitor of cell growth." 1990, Cell. Growth. Differ. 1:447-454.
NEWTON et al. "The human S100 protein MRP-14 is a novel activator of the β2 integrin Mac-1 on neutrophils." 1998, J. Immunol. 160:1427-1435.
ODINK et al. "Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis." 1987, Nature, 330: 80-82.
PECHKOVSKY et al. "Calprotectin (MRP8/14 protein complex) realease during mycobacterial infection in vitro and in vivo." 2000, FEMS. Immunol. Med. Microbiol. 29:27-33.
RAFTERY et al. "Novel intra-and inter-molecular sulfonamide bonds in S100A8 produced by hypochlorite oxidation." 2001, J. Biol. Chem. 276:33393-33401.
ROSETH et al. "Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease." 1999, Scand. J. Gastroenterol, 34:50-54.

Examiner	Date	
Signature	Considered	

^{*}EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.